Prognostic Value of Blasts in Peripheral Blood in Myelofibrosis in the Ruxolitinib Era

BACKGROUND: Peripheral blasts (PB) ≥1% have long been considered an unfavorable feature for patients with primary myelofibrosis (PMF). Whether further quantification of PB blasts and their correlation with bone marrow (BM) blasts has incremental value with regards to patient prognostication is uncle...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer
Hoofdauteurs: Masarova, Lucia, Bose, Prithviraj, Pemmaraju, Naveen, Daver, Naval G., Zhou, Lingsha, Pierce, Sherry, Sasaki, Koji, Kantarjian, Hagop, Estrov, Zeev, Verstovsek, Srdan
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2020
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7875207/
https://ncbi.nlm.nih.gov/pubmed/32697338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33094
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items